Haematologica Reports 2006; 2(issue 3): 50-51[prev][index][next]
Changes in bone resorption and vascular endothelial growth factor after a single
zoledronic acid infusion in cancer patients with bone metastases from solid tumours
Vincenzi B,1 Santini D,1 Holen I,2 Tonini G,1
Clinical Oncology, University Campus Bio-Medico, Rome, Italy;
Clinical Oncology, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
Purpose
Zoledronic acid (Zometa) is increasingly used to treat tumour-induced bone disease, and is also reported to have anti-angiogenic properties in vivo.1,2 In this study we have investigated the correlations between changes in the pro-angiogenic cytokine VEGF and markers of bone resorption in a cohort of patients with metastatic bone disease, following a single infusion of zoledronic acid.
[>Read full article in PDF]
